Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andrea Tan
GS
Andrea Tan
Goldman Sachs
Wall Street Analyst
★★★★★
#196
on 13Foresight · ranked by our own returns
87%
Success Rate
+20.0%
Average Return
13 of 15 calls profitable · +2.3% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 87% of Andrea Tan's ratings turned a profit when each position was held for 1 year — averaging +20.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

4 Buy 2 Hold 0 Sell
Andrea's Stock Coverage 15 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
TARS
Tarsus Pharmaceuticals
 Feb 05, 2026 HOLD Strong Buy
+20.6% avg upside
16 analysts
$68.00
7.74% Upside
 +2.9%
KRYS
Krystal Biotech
 Jan 30, 2026 BUY Strong Buy
-28.3% avg upside
19 analysts
$327.00
6.13% Downside
 +22.4%
MDGL
Madrigal Pharmaceuticals
 Aug 18, 2025 BUY Strong Buy
-5.8% avg upside
31 analysts
$567.00
12.08% Upside
 +22.8%
IOVA
Iovance Biotherapeutics
 Jun 03, 2025 BUY Strong Buy
+225.4% avg upside
24 analysts
$8.00
104.67% Upside
 +89.6%
ARWR
Arrowhead Pharmaceuticals
 Mar 10, 2025 HOLD Strong Buy
-19.1% avg upside
26 analysts
$26.00
68.26% Downside
 +289.2%
KOD
Kodiak Sciences
 Sep 24, 2024 SELL Buy
+37.6% avg upside
11 analysts
$2.00
94.53% Downside
 -493.5%
INSM
Insmed
 Aug 09, 2024 BUY Strong Buy
+82.1% avg upside
36 analysts
$103.00
7.50% Upside
 +48.1%
SGMT
Sagimet Biosciences, Inc. Class A
 Jun 28, 2024 HOLD Strong Buy
+317.2% avg upside
15 analysts
$6.00
10.19% Downside
 +130.1%
JAZZ
Jazz Pharmaceuticals
 Jun 05, 2024 BUY Strong Buy
-1.8% avg upside
35 analysts
$169.00
24.76% Downside
 +2.1%
RLMD
Relmada Therapeutics
 Jun 05, 2024 SELL Buy
+106.4% avg upside
15 analysts
$2.00
70.23% Downside
 +72.3%
TGTX
TG Therapeutics
 Jan 09, 2024 HOLD Strong Buy
-34.3% avg upside
19 analysts
 — +36.9%
CNTA
Centessa Pharmaceuticals
 Aug 15, 2023 HOLD Buy
-14.4% avg upside
19 analysts
$5.00
87.48% Downside
 +89.4%
ABCL
AbCellera Biologics
 Aug 04, 2023 BUY Strong Buy
+139.4% avg upside
15 analysts
$24.00
334.05% Upside
 -51.7%
FATE
Fate Therapeutics
 Jan 10, 2023 SELL Buy
+492.3% avg upside
31 analysts
$4.00
91.40% Upside
 +16.8%
VOR
Vor Biopharma
 May 24, 2022 HOLD Buy
+199.3% avg upside
17 analysts
$4.00
72.30% Downside
 +23.1%
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andrea Tan — Frequently Asked Questions
How accurate are Andrea Tan's stock ratings?
Based on the calls 13Foresight could measure, about 87% of Andrea's ratings were profitable over a one-year hold, with an average return of +20.0% per rating, or +2.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Andrea ranked on 13Foresight?
Andrea Tan is currently ranked #196 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andrea cover?
Andrea most recently has ratings on TARS, KRYS, MDGL, IOVA, ARWR, KOD, INSM, SGMT, JAZZ, RLMD, TGTX, CNTA and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.